Somewhat Positive News Coverage Somewhat Unlikely to Affect Puma Biotechnology (PBYI) Stock Price

Headlines about Puma Biotechnology (NASDAQ:PBYI) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Puma Biotechnology earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.6950241922059 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news headlines that may have impacted Accern’s rankings:

How to Become a New Pot Stock Millionaire

Shares of NASDAQ:PBYI opened at $68.05 on Friday. Puma Biotechnology has a 52 week low of $28.35 and a 52 week high of $136.90. The firm has a market capitalization of $2,566.85, a PE ratio of -8.67 and a beta of 0.26. The company has a debt-to-equity ratio of 0.91, a current ratio of 1.82 and a quick ratio of 1.79.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.71) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.98) by $0.27. The firm had revenue of $21.60 million during the quarter, compared to the consensus estimate of $20.83 million. During the same quarter in the previous year, the company posted ($1.22) earnings per share. analysts expect that Puma Biotechnology will post -4.07 EPS for the current year.

Several research firms have weighed in on PBYI. Credit Suisse Group cut their target price on Puma Biotechnology from $147.00 to $106.00 and set an “outperform” rating for the company in a research note on Wednesday, January 24th. BidaskClub cut Puma Biotechnology from a “buy” rating to a “hold” rating in a research note on Friday, January 26th. JPMorgan Chase cut their target price on Puma Biotechnology from $138.00 to $91.00 and set a “buy” rating for the company in a research note on Wednesday, January 24th. Bank of America cut their target price on Puma Biotechnology from $135.00 to $115.00 and set a “buy” rating for the company in a research note on Wednesday, January 24th. Finally, Royal Bank of Canada dropped their price target on Puma Biotechnology to $77.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $103.11.

In related news, insider Alan H. Auerbach sold 10,692 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total transaction of $991,683.00. Following the completion of the transaction, the insider now directly owns 4,155,931 shares of the company’s stock, valued at approximately $385,462,600.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Richard Paul Bryce sold 1,860 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $92.75, for a total value of $172,515.00. Following the transaction, the senior vice president now directly owns 25,379 shares of the company’s stock, valued at $2,353,902.25. The disclosure for this sale can be found here. 21.10% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This story was first published by WKRB News and is owned by of WKRB News. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://www.wkrb13.com/2018/04/01/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-puma-biotechnology-pbyi-stock-price.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Insider Buying and Selling by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply